{"id":"mellaril","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02600741","NCT02435095","NCT01231074","NCT02582736","NCT02307396","NCT02096289","NCT02191358","NCT01765803","NCT02374567","NCT00538122","NCT04002700"],"aliases":["Thioridazine"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Mellaril","companyId":"new-mexico-cancer-research-alliance","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"New Mexico Cancer Research Alliance","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Mellaril","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02600741","phase":"N/A","title":"A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and ","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","isPivotal":false,"enrollment":296,"indication":"Schizophrenia","completionDate":"2018-07-05"},{"nctId":"NCT02435095","phase":"Phase 4","title":"Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies","status":"TERMINATED","sponsor":"RWTH Aachen University","isPivotal":false,"enrollment":174,"indication":"Schizophrenia","completionDate":"2020-08"},{"nctId":"NCT01231074","phase":"Phase 1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","isPivotal":false,"enrollment":96,"indication":"Obesity, Weight Gain","completionDate":"2013-05"},{"nctId":"NCT02582736","phase":"N/A","title":"Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","isPivotal":false,"enrollment":725489,"indication":"Psychotic Disorders, Schizophrenia","completionDate":"2012-12"},{"nctId":"NCT02307396","phase":"Phase 4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitu","status":"COMPLETED","sponsor":"Technical University of Munich","isPivotal":false,"enrollment":21,"indication":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features","completionDate":"2016-06-22"},{"nctId":"NCT02096289","phase":"Phase 1","title":"A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease","status":"COMPLETED","sponsor":"Ontario Clinical Oncology Group (OCOG)","isPivotal":false,"enrollment":13,"indication":"Acute Myeloid Leukemia","completionDate":"2016-09"},{"nctId":"NCT02191358","phase":"N/A","title":"YouScript IMPACT (Improving Medication Protocols and Abating Cost of Treatment) Registry","status":"COMPLETED","sponsor":"Genelex Corporation","isPivotal":false,"enrollment":800,"indication":"Adverse Drug Events, Adverse Drug Reactions","completionDate":"2015-08"},{"nctId":"NCT01765803","phase":"EARLY/Phase 1","title":"A Single Institution Feasibility Study to Assess Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","isPivotal":false,"enrollment":6,"indication":"Healthy Subjects","completionDate":"2013-12"},{"nctId":"NCT02374567","phase":"Phase 3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","isPivotal":true,"enrollment":407,"indication":"Dementia, Depression","completionDate":"2017-06-28"},{"nctId":"NCT00538122","phase":"N/A","title":"Evaluating the Risks of Arrhythmia and Sudden Death Associated With Antipsychotic Drugs by Assessing the T Wave Abnormalities in the Holter Electrocardiogram","status":"COMPLETED","sponsor":"Vanderbilt University","isPivotal":false,"enrollment":12,"indication":"Schizophrenia, Schizoaffective Disorder","completionDate":"2008-09"},{"nctId":"NCT04002700","phase":"N/A","title":"Stroke Risk Among Users of Typical vs. Atypical Antipsychotics Stratified by Broad Age Group, a Post-authorization Safety Study","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":1234412,"indication":"Stroke","completionDate":"2019-05-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}